Angela Wahl

Angela Wahl

Auto-generated profile, based on publicly available information

Angela Wahl

Department of Microbiology, University of Alabama at Birmingham, Birmingham, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JHJenna B. Honeycutt
Jenna B. Honeycutt
AWAngela Wahl
Angela Wahl
CBCaroline Baker
Caroline Baker
RSRae Ann Spagnuolo
Rae Ann Spagnuolo
JFJohn Foster
John Foster
JGJ. Victor Garcia
J. Victor Garcia
Macrophages have long been considered to contribute to HIV infection of the CNS; however, a recent study has contradicted this early work and suggests that myeloid cells are not an in vivo source of virus production. Here, we addressed the role of macrophages in HIV infection by first analyzing monocytes isolated from viremic patients and patients undergoing antiretroviral treatment. We were unable to find viral DNA or viral outgrowth in monocytes isolated from peripheral blood. To determine whether tissue macrophages are productively infected, we used 3 different but complementary humanized mouse models. Two of these models (bone marrow/liver/thymus [BLT] mice and T cell–only mice [ToM]) have been previously described, and the third model was generated by reconstituting immunodeficient mice with human CD34+ hematopoietic stem cells that were devoid of human T cells (myeloid-only mice [MoM]) to specifically evaluate HIV replication in this population. Using MoM, we demonstrated that macrophages can sustain HIV replication in the absence of T cells; HIV-infected macrophages are distributed in various tissues including the brain; replication-competent virus can be rescued ex vivo from infected macrophages; and infected macrophages can establish de novo infection. Together, these results demonstrate that macrophages represent a genuine target for HIV infection in vivo that can sustain and transmit infection.

26 August 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AWAngela Wahl
Angela Wahl
CDChandrav De
Chandrav De
MFMaria Abad Fernandez
Maria Abad Fernandez
ELErik M. Lenarcic
Erik M. Lenarcic
YXYinyan Xu
Yinyan Xu
JGJ. Victor Garcia
J. Victor Garcia

4 June 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JHJenna B. Honeycutt
Jenna B. Honeycutt
BLBaolin Liao
Baolin Liao
CNChristopher C. Nixon
Christopher C. Nixon
RCRachel A. Cleary
Rachel A. Cleary
WTWilliam O. Thayer
William O. Thayer
JGJ. Victor Garcia
J. Victor Garcia
The human brain is an important site of HIV replication and persistence during antiretroviral therapy (ART). Direct evaluation of HIV infection in the brains of otherwise healthy individuals is not feasible; therefore, we performed a large-scale study of bone marrow/liver/thymus (BLT) humanized mice as an in vivo model to study HIV infection in the brain. Human immune cells, including CD4+ T cells and macrophages, were present throughout the BLT mouse brain. HIV DNA, HIV RNA, and/or p24+ cells were observed in the brains of HIV-infected animals, regardless of the HIV isolate used. HIV infection resulted in decreased numbers of CD4+ T cells, increased numbers of CD8+ T cells, and a decreased CD4+/CD8+ T cell ratio in the brain. Using humanized T cell–only mice (ToM), we demonstrated that T cells establish and maintain HIV infection of the brain in the complete absence of human myeloid cells. HIV infection of ToM resulted in CD4+ T cell depletion and a reduced CD4+/CD8+ T cell ratio. ART significantly reduced HIV levels in the BLT mouse brain, and the immune cell populations present were indistinguishable from those of uninfected controls, which demonstrated the effectiveness of ART in controlling HIV replication in the CNS and returning cellular homeostasis to a pre-HIV state.

24 October 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
JHJenna B Honeycutt
Jenna B Honeycutt
AWAngela Wahl
Angela Wahl
NANancie Archin
Nancie Archin
SCShailesh Choudhary
Shailesh Choudhary
DMDavid Michael M Margolis
David Michael M Margolis
JGJ. Victor Garcia
J. Victor Garcia
Background: The major targets of HIV infection in humans are CD4+T cells. CD4+T cell depletion is a hallmark of AIDS. Previously, the SCID-hu thy/liv model was used to study the effect of HIV on thymopoeisisin vivo. However, these mice did not develop high levels of peripheral T cell reconstitution and required invasive surgery for infection and analysis. Here, we describe a novel variant of this model in which thy/liv implantation results in systemic reconstitution with human T cells in the absence of any other human hematopoietic lineages.Results: NOD/SCID-hu thy/liv and NSG-hu thy/liv mice were created by implanting human fetal thymus and liver tissues under the kidney capsule of either NOD/SCID or NSG mice. In contrast to NOD/SCID-hu thy/liv mice that show little or no human cells in peripheral blood or tissues, substantial systemic human reconstitution occurs in NSG-hu thy/liv. These mice are exclusively reconstituted with human T cells (i.e. T-cell only mice or TOM). Despite substantial levels of human T cells no signs of graft-versus-host disease (GVHD) were noted in these mice over a period of 14 months. TOM are readily infected after parenteral exposure to HIV-1. HIV replication is sustained in peripheral blood at high levels and results in modest reduction of CD4+T cells. HIV-1 replication in TOM responds to daily administration of combination antiretroviral therapy (ART) resulting in strong suppression of virus replication as determined by undetectable viral load in plasma. Latently HIV infected resting CD4+T cells can be isolated from suppressed mice that can be induced to express HIVex-vivoupon activation demonstrating the establishment of latencyin vivo.Conclusions: NSG-hu thy/liv mice are systemically reconstituted with human T cells. No other human lymphoid lineages are present in these mice (i.e. monocytes/macrophages, B cells and DC are all absent). These T cell only mice do not develop GVHD, are susceptible to HIV-1 infection and can efficiently maintain virus replication. HIV infected TOM undergoing ART harbor latently infected, resting CD4+T cells.

8 June 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
CDChandrav De
Chandrav De
RPRaymond Pickles
Raymond Pickles
WYWenbo Yao
Wenbo Yao
BLBaolin Liao
Baolin Liao
ABAllison Boone
Allison Boone
AWAngela Wahl
Angela Wahl
Respiratory syncytial virus (RSV) infection causes significant morbidity and mortality in infants, immunocompromised individuals, and older individuals. There is an urgent need for effective antivirals and vaccines for high-risk individuals. We used 2 complementary in vivo models to analyze RSV-associated human lung pathology and human immune correlates of protection. RSV infection resulted in widespread human lung epithelial damage, a proinflammatory innate immune response, and elicited a natural adaptive human immune response that conferred protective immunity. We demonstrated a key role for human T cells in controlling RSV infection. Specifically, primed human CD8 + T cells or CD4 + T cells effectively and independently control RSV replication in human lung tissue in the absence of an RSV-specific antibody response. These preclinical data support the development of RSV vaccines, which also elicit effective T cell responses to improve RSV vaccine efficacy.

15 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KRKathryn L. Roche
Kathryn L. Roche
SRStacy Remiszewski
Stacy Remiszewski
MTMatthew J. Todd
Matthew J. Todd
JKJohn L Kulp
John L Kulp
LTLiudi Tang
Liudi Tang
LCLillian W. Chiang
Lillian W. Chiang
Most drugs used to treat viral disease target a virus-coded product. They inhibit a single virus or virus family, and the pathogen can readily evolve resistance. Host-targeted antivirals can overcome these limitations. The broad-spectrum activity achieved by host targeting can be especially useful in combating emerging viruses and for treatment of diseases caused by multiple viral pathogens, such as opportunistic agents in immunosuppressed patients. We have developed a family of compounds that modulate sirtuin 2, an NAD+-dependent deacylase, and now report the properties of a member of that family, FLS-359. Biochemical and x-ray structural studies show that the drug binds to sirtuin 2 and allosterically inhibits its deacetylase activity. FLS-359 inhibits the growth of RNA and DNA viruses, including members of the coronavirus, orthomyxovirus, flavivirus, hepadnavirus, and herpesvirus families. FLS-359 acts at multiple levels to antagonize cytomegalovirus replication in fibroblasts, causing modest reductions in viral RNAs and DNA, together with a much greater reduction in infectious progeny, and it exhibits antiviral activity in humanized mouse models of infection. Our results highlight the potential of sirtuin 2 inhibitors as broad-spectrum antivirals and set the stage for further understanding of how host epigenetic mechanisms impact the growth and spread of viral pathogens.